CLINICAL TRIALS PROFILE FOR AURYXIA
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Auryxia
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01554982 ↗ | A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis | Completed | Keryx Biopharmaceuticals | Phase 3 | 2012-08-01 | A long-term safety study of ferric citrate (KRX-0502) in renal failure patients who have completed study KRX-0502-304. Only patients who participated in the KRX-0502-304 trial may participate in this trial. |
| NCT02492620 ↗ | Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D | Completed | Keryx Biopharmaceuticals | Phase 3 | 2015-03-01 | It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy. |
| NCT02492620 ↗ | Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D | Completed | Denver Nephrologists, P.C. | Phase 3 | 2015-03-01 | It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy. |
| NCT02661295 ↗ | A Study of Ferric Citrate to Improve Inflammation and Lipid Levels | Unknown status | Keryx Biopharmaceuticals | Phase 4 | 2015-07-01 | The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis is 10-100 times higher than the normal population. This is due in part to high levels of inflammation and vascular calcification found in these patients. Phosphate binders, particularly non-calcium based phosphate binders, may decrease cardiovascular risk by decreasing inflammation and vascular calcification. Ferric citrate a non-calcium based phosphate binder with approximately 210 mg of ferric iron has recently been approved for patients on hemodialysis. The effect of this phosphate binder on inflammation and lipid levels is unknown but investigators hypothesize that ferric citrate has the potential to improve inflammation and lipid levels in patients on hemodialysis by decreasing intravenous iron requirements and by improving lipid metabolism. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Auryxia
Condition Name
Clinical Trial Locations for Auryxia
Trials by Country
Clinical Trial Progress for Auryxia
Clinical Trial Phase
Clinical Trial Sponsors for Auryxia
Sponsor Name
